Recombinant interferons in the management of advanced malignant melanoma. Updated review of five prospective clinical trials and long-term responders.

PubWeight™: 0.81‹?›

🔗 View Article (PMID 3142248)

Published in Am J Clin Oncol on December 01, 1988

Authors

E T Creagan1, D J Schaid, D L Ahmann, S Frytak

Author Affiliations

1: Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905.

Articles by these authors

Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med (1999) 7.81

Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered (2003) 5.06

Evaluation of candidate genes in case-control studies: a statistical method to account for related subjects. Am J Hum Genet (2001) 4.09

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer (1981) 3.86

Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA (1995) 3.84

Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst (1999) 3.46

Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst (2001) 3.37

Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res (1998) 3.36

Incidence of reading disability in a population-based birth cohort, 1976-1982, Rochester, Minn. Mayo Clin Proc (2001) 3.18

The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet (2001) 2.68

Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med (1979) 2.63

Extrapulmonary small cell carcinoma. Cancer (1997) 2.61

Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med (2001) 2.41

Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study. Neurology (2000) 2.31

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol (1993) 2.28

Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord (2000) 2.20

Potential influence of migration bias in birth cohort studies. Mayo Clin Proc (1998) 2.19

Case-control studies of genetic markers: power and sample size approximations for Armitage's test for trend. Hum Hered (2001) 2.14

Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med (1998) 1.96

Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst (1990) 1.92

Sequence analysis of the fragile X trinucleotide repeat: implications for the origin of the fragile X mutation. Hum Mol Genet (1994) 1.90

Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet (1994) 1.83

Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine (2001) 1.77

Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med (1978) 1.74

Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med (1981) 1.70

Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet (2000) 1.69

Familial aneurysmal subarachnoid hemorrhage: a community-based study. J Neurosurg (1995) 1.68

Germ-line origins of mutation in families with hemophilia B: the sex ratio varies with the type of mutation. Am J Hum Genet (1993) 1.66

Validation of a telephone questionnaire for Parkinson's disease. J Clin Epidemiol (1998) 1.65

Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol (2001) 1.63

Malignant lymphoma of the spleen. A review of 49 cases in which the diagnosis was made at splenectomy. Cancer (1966) 1.54

Phase II evaluation of menogaril in patients with advanced hypernephroma. Invest New Drugs (1991) 1.53

A comparative evaluation of marketed analgesic drugs. N Engl J Med (1972) 1.50

The location of the Philadelphia chromosomal breakpoint site and prognosis in chronic granulocytic leukemia. Leukemia (1990) 1.49

Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology (1997) 1.46

Hereditary motor and sensory neuropathy type 2C is genetically distinct from types 2B and 2D. Arch Neurol (2000) 1.45

Validity of family history data on PD: evidence for a family information bias. Neurology (2003) 1.41

Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA (2000) 1.40

Radiation therapy for squamous cell carcinoma of the tonsil. Mayo Clin Proc (1994) 1.39

Candidate-gene association studies with pedigree data: controlling for environmental covariates. Genet Epidemiol (2003) 1.36

Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord (2001) 1.35

SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet (2009) 1.32

The genomic organization of human dystrobrevin. Neurogenetics (1997) 1.29

Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res (1996) 1.28

Hereditary motor and sensory neuropathy with diaphragm and vocal cord paresis. Ann Neurol (1994) 1.26

Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer. Cancer Chemother Rep (1975) 1.25

Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res (2001) 1.24

The gene for HMSN2C maps to 12q23-24: a region of neuromuscular disorders. Neurology (2003) 1.22

Genetic heterogeneity in Peutz-Jeghers syndrome. Hum Mutat (2000) 1.22

Microsatellite instability in Muir-Torre syndrome. Cancer Res (1994) 1.19

Potential misinterpretation of the case-only study to assess gene-environment interaction. Am J Epidemiol (1999) 1.19

Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells. Hum Mol Genet (1994) 1.19

Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer (1989) 1.18

Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol (1986) 1.15

Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med (1979) 1.14

Choosing a pediatric recipient for orthotopic liver transplantation. J Pediatr (1987) 1.14

Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer (1991) 1.13

Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses. Cancer (1987) 1.12

Relief of pain by oral medications. A controlled evaluation of analgesic combinations. JAMA (1974) 1.12

Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas. J Clin Invest (1991) 1.11

Expression of p53 and 17p allelic loss in colorectal carcinoma. Cancer Res (1992) 1.11

Management of nausea and vomiting in the cancer patient. JAMA (1981) 1.11

Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology (1998) 1.10

Confirmation of linkage of prostate cancer aggressiveness with chromosome 19q. Am J Hum Genet (2003) 1.10

Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res (1998) 1.09

Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol (1993) 1.07

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol (1995) 1.05

Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am J Hum Genet (2000) 1.04

Progression of familial and non-familial dilated cardiomyopathy: long term follow up. Heart (2003) 1.03

A phase I clinical trial of recombinant human tumor necrosis factor. Cancer (1988) 1.02

Association of Peutz-Jeghers-like mucocutaneous pigmentation with breast and gynecologic carcinomas in women. Medicine (Baltimore) (2000) 1.01

Current status of adjuvant chemotherapy for colorectal cancer. Can molecular markers play a role in predicting prognosis? Cancer (1992) 1.00

Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol (1987) 0.98

Autosomal dominant supravalvular aortic stenosis: localization to chromosome 7. Hum Mol Genet (1993) 0.97

A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer (1990) 0.97

Genetic diversity and function in the human cytosolic sulfotransferases. Pharmacogenomics J (2006) 0.97

Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol (1986) 0.97

Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group Report. Cancer (1978) 0.96

Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma. Cancer (1982) 0.96

Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens. Blood (1992) 0.96

Phase II study of tamoxifen in patients with disseminated malignant melanoma. Cancer Treat Rep (1980) 0.96

Novel pattern of P53 mutation in breast cancers from Austrian women. J Clin Invest (1995) 0.95

Cerebral toxicity in patients treated for small cell carcinoma of the lung. Mayo Clin Proc (1999) 0.95

Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. Cancer Chemother Rep (1975) 0.95

Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors. Cancer (1993) 0.95

The urinary excretion of nucleosides of ribonucleic acid by patients with advanced cancer. Cancer (1975) 0.94

Base of tongue carcinoma: patterns of failure and predictors of recurrence after surgery alone. Head Neck (1993) 0.94

Tumor necrosis factor-alpha allelic frequency and chromosome 6 allelic imbalance in patients with colorectal cancer. Cancer Res (1996) 0.94

Randomized study of systemic chemotherapy following complete excision of nonosseous sarcomas. J Clin Oncol (1984) 0.93

Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol (1993) 0.93

Complete responders to chemotherapy in metastatic breast cancer. Characterization and analysis. JAMA (1979) 0.93

Alpha-1-antitrypsin phenotypes among patients with intracranial aneurysms. J Neurosurg (1996) 0.92

Germline origins in the human F9 gene: frequent G:C-->A:T mosaicism and increased mutations with advanced maternal age. Hum Genet (1999) 0.91

On the inheritance of intracranial aneurysms. Stroke (1994) 0.91

Primary mediastinal choriocarcinoma. Mayo Clin Proc (1968) 0.91

A design for phase II testing of anticancer agents within a phase III clinical trial. Control Clin Trials (1988) 0.91

Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees. Genet Epidemiol (2001) 0.90

Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients. Cancer Treat Rep (1986) 0.90